Literature DB >> 35863604

The infectivity and pathogenicity of hepatitis A virus live-attenuated vaccine strain H2 in type I interferon receptor-deficient mice.

Qing-Qing Ma1, Hong-Jiang Wang2, Jian Li3, Meng-Qi Li1, Tian-Shu Cao1, Xiao-Yan Wu1, Hong-Ying Qiu1, Hui Zhao4, Cheng-Feng Qin5.   

Abstract

Hepatitis A virus (HAV) live-attenuated vaccine H2 strain has been approved for clinical use for decades with ideal safety profiles in nonhuman primate models and humans. Recently, type I interferon (IFN) receptor-deficient mice were shown to be susceptible to HAV infection. Herein, we sought to determine the infection and replication dynamics of the H2 in Ifnar-/- mice that lack type I IFN receptor. Following intravenous injection, the H2 failed to cause obvious clinical symptoms in Ifnar-/- mice, and no significant upregulation in serum alanine aminotransferase (ALT) levels was observed. Notably, the histopathological examination showed that there were significant focal infiltrations of lymphocytes and neutrophils in the portal area, but no focal necrosis was observed in liver tissues. Viral RNAs sustained in the liver, and the infectious virus could be recovered from the liver tissue until 42 days post-infection. More importantly, H2 infection induced obvious viremia and persistent viral shedding in feces. In addition, robust HAV-specific humoral immune responses were induced in Ifnar-/- mice. Overall, our study revealed the safety profile of H2 in Ifnar-/- mice, which not only helps understand the attenuation mechanism of H2, but also expands the application of the Ifnar-/- mouse model for HAV studies.
Copyright © 2022 The Authors. Publishing services by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatitis A; Hepatitis A virus (HAV); Live-attenuated vaccine; Mouse model

Mesh:

Substances:

Year:  2022        PMID: 35863604      PMCID: PMC9583102          DOI: 10.1016/j.virs.2022.07.009

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   6.947


  24 in total

1.  Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin.

Authors:  S M Lemon; P C Murphy; P J Provost; I Chalikonda; J P Davide; T L Schofield; D R Nalin; J A Lewis
Journal:  J Infect Dis       Date:  1997-07       Impact factor: 5.226

2.  Experimental hepatitis A virus infection in guinea pigs.

Authors:  B Hornei; R Kämmerer; P Moubayed; W Frings; V Gauss-Müller; A Dotzauer
Journal:  J Med Virol       Date:  2001-08       Impact factor: 2.327

Review 3.  Immunobiology and pathogenesis of viral hepatitis.

Authors:  Luca G Guidotti; Francis V Chisari
Journal:  Annu Rev Pathol       Date:  2006       Impact factor: 23.472

4.  Effect of postexposure vaccination in a chimpanzee model of hepatitis A virus infection.

Authors:  B H Robertson; E H D'Hondt; J Spelbring; H Tian; K Krawczynski; H S Margolis
Journal:  J Med Virol       Date:  1994-07       Impact factor: 2.327

5.  [Experimental in vivo passage of H2 strain of live attenuated vaccine of hepatitis A in common marmosets].

Authors:  X Huang; Y Lian; Q Wang
Journal:  Zhonghua Yu Fang Yi Xue Za Zhi       Date:  1997-09

6.  Susceptibility of monkeys to human hepatitis A virus.

Authors:  J S Mao; Y Y Go; H Y Huang; P H Yu; B Z Huang; Z S Ding; N L Chen; J H Yu; R Y Xie
Journal:  J Infect Dis       Date:  1981-07       Impact factor: 5.226

7.  Era of vaccination heralds a decline in incidence of hepatitis A in high-risk groups in China.

Authors:  Zhuang Fangcheng; Wang Xuanyi; Chen Mingding; Jiang Liming; Wu Jie; Jiang Qi; Gong Yuanping; Qian Wen; Xin Yajuan; Mao Jiangsen
Journal:  Hepat Mon       Date:  2012-02-29       Impact factor: 0.660

8.  Biliary Secretion of Quasi-Enveloped Human Hepatitis A Virus.

Authors:  Asuka Hirai-Yuki; Lucinda Hensley; Jason K Whitmire; Stanley M Lemon
Journal:  mBio       Date:  2016-12-06       Impact factor: 7.867

Review 9.  Review of long term immunogenicity and tolerability of live hepatitis A vaccine.

Authors:  Nitin Shah; Mma Faridi; Monjori Mitra; Ashish Bavdekar; Archana Karadkhele; Gaurav Puppalwar; Rishi Jain
Journal:  Hum Vaccin Immunother       Date:  2020-04-03       Impact factor: 3.452

10.  T cells protect against hepatitis A virus infection and limit infection-induced liver injury.

Authors:  Ichiro Misumi; Joseph E Mitchell; Makayla M Lund; John M Cullen; Stanley M Lemon; Jason K Whitmire
Journal:  J Hepatol       Date:  2021-07-29       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.